Adding Relacorilant To Nab-paclitaxel Prolongs Survival Compared with a Weekly Taxane in Patients with Platinum-Resistant Epithelial Ovarian Cancer By Ogkologos - June 23, 2025 655 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ROSELLA study Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR Liquid Biopsies for Cancer: What to Know and What to Expect November 3, 2022 New Research in Treating Non-Hodgkin Lymphoma and Predicting the Risk of... January 26, 2023 Smoking addiction killed my grandfather – now it’s up to the... December 29, 2022 27-Year-Old Diagnosed with Cancer at 20 Weeks Pregnant Gives Birth Amid... July 3, 2020 Load more HOT NEWS American tobacco company Philip Morris International offers £1bn for UK pharma... Can Artificial Intelligence–Driven Chatbots Correctly Answer Questions about Cancer? Cancer Survivor with Strong Family History Was Denied Regular Screening Because... FDA Approves Retifanlimab-dlwr with Carboplatin and Paclitaxel and as a Single...
